Semiconductor and AI infrastructure sectors led market losses today, weighed down by Nebius’s lowered guidance, analyst downgrades, and a sharp reversal in AMD shares. Meanwhile, strong earnings and insider buying boosted healthcare stocks like Steris and Alnylam Pharmaceuticals.
GAINERS
Alnylam Pharmaceuticals (+6%) : The company’s director Amy W Schulman executed a purchase of 1,910 shares worth $299,526, which lifted its stock.
Steris (+4%): Besides reporting a robust Q2 revenue of $1.6bn, exceeding analysts target of $1.56bn, the medical equipment supplier’s rating got upgraded by Jefferies from Hold to Buy, adjusting its price target to $305.
Applovin (+3.2%) : Daiwa Securities maintained its Outperform rating and raised the mobile marketing’s corporation target price from $345 to $455, meaning analysts recommend buying shares.
LOSERS
Nebius (-12.8%) : Delivery delays at several data centers, particularly in New Jersey, have forced Nebius to lower its full-year revenue forecast to $3-3.2bn, while raising its investments to $27bn. It now targets $12-13bn in revenue in 2027, at the cost of an additional $40-45bn in investments, intensifying questions about the financing and profitability of this expansion.
AMD (-9.50%) : Traders rushed into buying the semiconductor company’s shares yesterday following the abrupt resignation of Nvidia CEO Jensen Huang, betting AMD would capture market share during Nvidia’s leadership instability. As Nvidia shares began stabilizing this morning, hedge funds and short-term traders quickly unwound those rotation bets.
Broadcom (-6.6%) : Rothschild & Co Redburn jus downgraded Broadcom from Buy to Neutral with a $398.46 price target.
Leave a Reply